匹多莫德防治脑性瘫痪患儿反复呼吸道感染72例临床观察

Clinical Observation of Pidotimod on Preventing Recurrent Respiratory Tract Infection of Children with Cerebral Palsy

目的:观察匹多莫德防治脑性瘫痪(简称脑瘫)患儿反复呼吸道感染(RRI)的临床疗效及安全性。方法:将72例脑瘫合并RRI患儿随机分成观察组37例和对照组35例。两组患儿同时进行康复治疗,观察组加服匹多莫德每次400 mg,每天1次,持续服用60 d。观察两组患儿的临床症状,血清免疫球蛋白Ig A、Ig G、Ig M水平,肝肾功能,外周血象变化及不良反应。结果:治疗后,观察组Ig A、Ig G水平比治疗前升高(P<0.05),但Ig M与治疗前比较差异无统计学意义(P>0.05);对照组Ig A、Ig G、Ig M水平与治疗前比较差异均无统计学意义(P均>0.05)。与对照组比较,观察组呼吸道感染次数减少,发热时间、抗生素使用时间、咳嗽时间均缩短(P<0.05)。两组患儿治疗后BUN水平、ALT水平、WBC计数与治疗前比较差异均无统计学意义(P>0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论:匹多莫德用于防治脑瘫患儿RRI安全有效,值得临床推广应用。

Objective： To observe the clinical efficacy and safety of pidotimod on preventing recurrent respiratory tract infection of children with cerebral palsy. Methods： Seventy two children with cerebral palsy and recurrent respiratory tract infection were randomly divided into observation group（ 37 cases） and control group（ 35 cases）. All children of the two groups were given rehabilitation,the observation group were taken pidotimod,400 mg a time,one time a day for 60 days. The clinical symptoms,the levels of serum immune globulin（ Ig A,Ig G,Ig M） and the adverse reactions of two groups were observed. Results： After treatment,the levels of Ig A,Ig G except for Ig M increased obviously in observation group（ P〈0.05）. In comparison of the control group,the number of respiratory tract infection,the time of fever,antibiotic therapy and cough in observation group were significantly decreased,and the differences were statistically significant（ P〈0.05）. The incidence of adverse reactions between the two groups was not statistically significant（ P〉0. 05）.Conclusion： The effect of pidotimod on preventing recurrent respiratory tract infection of the children with cerebral palsy is good and safe.